PMID- 31487837
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Electronic)
IS  - 2079-6382 (Linking)
VI  - 8
IP  - 3
DP  - 2019 Sep 4
TI  - Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin 
      Structure Infection: A Systematic Review and Meta-Analysis.
LID - 10.3390/antibiotics8030137 [doi]
LID - 137
AB  - This meta-analysis aims to assess the efficacy and safety of tedizolid, compared 
      to linezolid, in the treatment of acute bacterial skin and skin structure 
      infection (ABSSSI). PubMed, Web of Science, EBSCO (Elton B. Stephens Co.), 
      Cochrane Library, Ovid Medline and Embase databases were accessed until 18 July 
      2019. Only randomized controlled trials (RCTs) comparing the efficacy of 
      tedizolid with linezolid for adult patients with ABSSSIs were included. The 
      outcomes included the clinical response, microbiological response, and risk of 
      adverse events (AEs). A total of four RCTs involving 2056 adult patients with 
      ABSSSI were enrolled. The early clinical response rate was 79.6% and 80.5% for 
      patients receiving tedizolid and linezolid, respectively. The pooled analysis 
      showed that tedizolid had a non-inferior early clinical response rate to 
      linezolid (odds ratio (OR) = 0.96, 95% confidence interval (CI) = 0.77-1.19, I(2) 
      = 0%). The early response rate was similar between tedizolid and linezolid among 
      patients with cellulitis/erysipelas (75.1% vs. 77.1%; OR = 0.90, 95% CI = 
      0.64-1.27, I(2) = 25%), major cutaneous abscess (85.1% vs. 86.8%; OR = 0.93, 95% 
      CI = 0.42-2.03, I(2) = 37%) and wound infection (85.9% vs. 82.6%; OR = 1.29, 95% 
      CI = 0.66-2.51, I(2) = 45%). For methicillin-resistant Staphylococcus aureus 
      patients, tedizolid had a favorable microbiological response rate of 95.2% which 
      was comparable to linezolid (94%) (OR = 1.19, 95% CI = 0.49-2.90, I(2) = 0%). In 
      addition to the similar risk of treatment-emergent AEs (a serious event, the 
      discontinuation of the study drug due to AEs and mortality between tedizolid and 
      linezolid), tedizolid was associated with a lower risk of nausea, vomiting and 
      abnormal neutrophil count than linezolid. In conclusion, once-daily tedizolid 
      (200 mg for six days) compared to linezolid (600 mg twice-daily for 10 days) was 
      non-inferior in efficacy in the treatment of ABSSSI. Besides, tedizolid was 
      generally as well tolerated as linezolid, and had a lower incidence of 
      gastrointestinal AEs and bone marrow suppression than linezolid.
FAU - Lan, Shao-Huan
AU  - Lan SH
AUID- ORCID: 0000-0002-8663-3161
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian 351100, China. shawnlan0713@gmail.com.
FAU - Lin, Wei-Ting
AU  - Lin WT
AD  - Department of Orthopedic, Chi Mei Medical Center, Tainan 71004, Taiwan. 
      aapriliaa@gmail.com.
AD  - Department of Physical Therapy, Shu Zen Junior College of Medicine and 
      Management, Kaohsiung 82144, Taiwan. aapriliaa@gmail.com.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Yijia Pharmacy, Tainan 70846, Taiwan. httremoon@ms.szmc.edu.tw.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, Putian 351100, China. 
      jane90467@gmail.com.
FAU - Chao, Chien-Ming
AU  - Chao CM
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, 
      Taiwan. ccm870958@yahoo.com.tw.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AUID- ORCID: 0000-0002-6334-2388
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan 71051, Taiwan. dtmed141@gmail.com.
FAU - Wang, Jui-Hsiang
AU  - Wang JH
AD  - Department of Internal Medicine, Division of Infection Disease, Kaohsiung 
      Veterans General Hospital, Tainan Branch, Tainan 71051, Taiwan. 
      hemletkimo@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20190904
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC6784229
OTO - NOTNLM
OT  - acute bacterial skin and skin structure infection
OT  - linezolid
OT  - tedizolid
COIS- The authors declare no conflict of interest.
EDAT- 2019/09/07 06:00
MHDA- 2019/09/07 06:01
PMCR- 2019/09/04
CRDT- 2019/09/07 06:00
PHST- 2019/08/05 00:00 [received]
PHST- 2019/08/29 00:00 [revised]
PHST- 2019/09/02 00:00 [accepted]
PHST- 2019/09/07 06:00 [entrez]
PHST- 2019/09/07 06:00 [pubmed]
PHST- 2019/09/07 06:01 [medline]
PHST- 2019/09/04 00:00 [pmc-release]
AID - antibiotics8030137 [pii]
AID - antibiotics-08-00137 [pii]
AID - 10.3390/antibiotics8030137 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2019 Sep 4;8(3):137. doi: 10.3390/antibiotics8030137.